GTHX - G1 Therapeutics Value Adjusted for Debt and Cash

Geopolitical tensions and sanctions are restricting drug exports and access to foreign raw materials, impacting the profits of G1 Therapeutics, Inc. (GTHX). This chart of the asset's value, which currently stands at , reflects the company's dynamics. The business relies on sales of Cosela for bone marrow protection, ensuring a stable cash flow, while also implementing robotic molecule screening and the automation of clinical data analysis.

From a portfolio management perspective, this indicator determines the total value of an asset by summing market capitalization and net debt to identify the objective acquisition price of a business. By analyzing the actual buyout cost, an investor can see how the monopoly status of G1 Therapeutics (GTHX) with its drug Cosela influences the company's valuation, eliminating distortions caused by the volume of available cash.